Open AccessLyell's syndrome and antimalarials: A case report and clinical review
Author(s) -
Joana Miranda Nunes,
Sofia Santareno,
Lina Guerreiro,
Ana Filipa Margalho
Publication year - 2017
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/0974-777x.199994
Subject(s) - toxic epidermal necrolysis , medicine , mucocutaneous zone , chemoprophylaxis , dermatology , intensive care medicine , drug , immunology , pediatrics , surgery , pathology , disease , psychiatry
Toxic epidermal necrolysis (TEN) or Lyell's syndrome is a rare, however, life-threatening mucocutaneous disorder with an epidermal detachment of a total body surface area (TBSA) of >30%. It is triggered by an idiosyncratic immune-allergic reaction to a drug, with many possible drugs implicated. Treatment success relies on early diagnosis and withdrawal of suspected/causative drug(s) and supportive care. Clinical evidence for specific therapies is still sparse. It is described a case of Lyell syndrome by sulfonamides for chemoprophylaxis of malaria. The patient presented with an extensive, rapidly evolving skin detachment, which progressed, despite supportive therapy, involving about 80% of TBSA. This led us to initiate a course of immunoglobulin with good clinical response. The aim of this work is to provide a discussion of the case and simultaneously make a practical literature review of TEN.